TLDR Some blood donors on teratogenic drugs may have unsafe drug levels, suggesting a need for better deferral policies.
The study analyzed 167 stored blood specimens from donors who had taken teratogenic drugs and whose blood was transfused to women of childbearing age. The aim was to determine the plasma concentration of these drugs at the time of donation using high-performance liquid chromatography. The results showed that the numbers of specimens exceeding the quantification limit were 7 for finasteride, 39 for isotretinoin, 4 for acitretin, 2 for etretinate, and 1 for dutasteride. Notably, one specimen of finasteride was beyond the recommended drug deferral period. These findings were intended to aid in the development of practical deferral policies for blood donors on teratogenic medications.
26 citations
,
January 2009 in “Transfusion Medicine and Hemotherapy” Donors on most medications can donate certain blood products without waiting, except for specific drugs that need a waiting period.
18 citations
,
October 2018 in “Journal of The American Academy of Dermatology” Some skin medications can harm male fertility, but they don't seem to cause birth defects from father's exposure.
11 citations
,
March 2019 in “Journal of The American Academy of Dermatology” Some men taking finasteride for hair loss may experience sexual problems like erectile dysfunction and decreased sex drive, which can persist even after stopping the medication.
38 citations
,
January 2019 in “International Journal of Women's Dermatology” The document concluded that more research is needed to find the best treatment for Frontal fibrosing alopecia.
3 citations
,
January 2012 in “Elsevier eBooks” The document says that there are treatments for hair and nail diseases.
1 citations
,
April 2010 in “Expert Review of Dermatology” The document concludes that early diagnosis and treatment are crucial for managing rare hair loss disorders and that more research is needed to improve treatment strategies.